ArticleScientific reports2025
Lactoferrin based copper nanoparticles: a promising anti-cancer strategy against malignant melanoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioactive Substances in Sheep's Milk and Related Products as Components of Functional Foods.Molecules (Basel, Switzerland) · 2026Review
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles.RSC advances · 2026Article
- Curcumin-stabilized silver nanoparticles target the Helicobacter pylori-tumor interface in gastric cancer.Scientific reports · 2026Article
- Lactoferrin as a Novel Therapeutic Agent in Dermatology: Current Evidence and Future Perspectives.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Skin cancer is one of the common malignancies worldwide, with malignant melanoma being its most aggressive and deadly form due to its high metastatic potential and resistance to conventional treatments. This underscores need for innovative treatment strategies. Protein-based nanoparticles known for enhanced bioavailability, targeted drug delivery, and reduced systemic toxicity, have emerged as promising tools against oncology. Lactoferrin, a multifunctional non-heme glycoprotein, exhibits diverse biological applications, including antimicrobial, antiviral, antiparasitic, and anti-cancer abilities. Current work reports the synthesis of spherical lactoferrin-coated copper nanoparticles (Cu-LFNPs) and evaluated for their anti-melanoma and antibacterial potential. The synthesized Cu-LFNPs exhibit enhanced stability, water solubility, drug loading efficiency (86.14 ± 3.45%), and sustained release profile (86.99 ± 1.77% release in 36 h). The Cu-LFNPs exhibit significant toxicity against A375 melanoma cells, reducing cell viability to 23.24 ± 1.84% at 40 µg/mL which is further supported by scratch assay. These findings suggest that Cu-LFNPs exhibit colossal potential to serve as an effective therapeutic strategy against malignant melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.